How much revenue does Scholar Rock Holding make?

Scholar Rock Holding reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.

What companies are similar to Scholar Rock Holding?

Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Praxis Precision Medicines, Inc. (PRAX), Alkermes plc (ALKS), PTC Therapeutics, Inc. (PTCT), Acadia Pharmaceuticals Inc. (ACAD).

Scholar Rock Holding Corporation (SRRK) Stock

About Scholar Rock Holding Corporation

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of ...

At a glance

Scholar Rock Holding reported revenue of $0 for fiscal year 2025, and net income of -$377.94 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.